查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1864213

心肺體外迴圈裝置市場按產品類型、應用、最終用戶和技術分類－2025年至2032年全球預測

Cardiopulmonary Bypass Equipment Market by Product Type, Application, End User, Technology - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，心肺體外迴圈設備市場規模將達到 4.561 億美元，複合年成長率為 4.53%。

關鍵市場統計數據
基準年 2024 3.1992億美元
預計年份：2025年 3.3474億美元
預測年份 2032 4.561億美元
複合年成長率 (%) 4.53%

對臨床實務、採購重點、技術進步以及心肺體外迴圈設備在機構決策架構中的定位進行策略概述

本執行摘要首先將心肺體外迴圈置於心臟外科手術的綜合治療系統中，指出設備的可靠性、生物相容性和手術效率直接影響臨床結果。體外循環設備包括用於心血管手術期間體外循環的裝置和一次性耗材，並與臨床通訊協定、灌注師操作規範和機構採購重點密切相關。隨著各醫院和專科心臟中心的團隊調整工作流程以最佳化治療效果並控制成本，了解設備功能、使用者人體工學和病人安全之間的相互作用至關重要。

臨床應用受微觀層面操作需求（例如易於安裝、預充量和與監測系統的兼容性）以及宏觀層面因素（例如監管和供應鏈韌性）的影響。氧合器膜設計和泵浦機制的技術進步降低了併發症率並簡化了手術全期管理，但也對培訓、耗材庫存和供應商提出了新的要求。因此，醫院管理者和循環系統支援負責人必須將臨床表現數據與採購考量結合，以選擇符合本院病例組合和長期資本規劃的系統。

本摘要的其餘部分以可操作的綜合形式呈現，重點介紹結構變化、政策影響、細分細微差別、區域趨勢、競爭對手行動以及具體建議，這些內容共同構成了製造商、供應商和投資者即時採取戰略行動的基礎。

膜設計、泵浦機制、塗層和臨床工作流程的進步正在共同重塑採購、臨床應用和設備開發路徑。

心肺體外迴圈領域正經歷變革性的轉變，這主要由臨床需求、技術創新以及對安全性和效率日益成長的期望共同驅動。膜式氧合器材料的進步，包括改良的中空纖維和平板式設計，在改善氣體交換特性的同時，也減少了血液損傷。同時，泵浦技術也朝著更耐用的離心機構和更精確的滾壓幫浦控制方向發展，從而改變了灌注師的工作流程和設備配置。

除了設備本身的改進之外，系統性轉變也顯而易見，重點在於透過塗層和表面處理來降低血栓形成風險。在抗凝血管理複雜的情況下，肝素塗層迴路和其他生物相容性塗層正日益受到重視，這使得塗層系統和非塗層系統之間形成了差異化的價值提案。操作模式（非搏動流與搏動流）的考量也影響醫院的採購決策，臨床醫師需要在血流動力學精確度、設備複雜性和耗材成本之間進行權衡。

在操作方面，積體電路組和一次性平台的使用趨勢日益明顯，這些設備有望實現更快的換型速度和更低的污染風險，但這些優勢必須與廢棄物管理和永續性目標相平衡。同時，新生兒和兒科領域的設備應用模式也對低流量和不同預充策略的專用插管和氧合器提出了更高的要求，迫使供應商針對不同的患者群體改進產品。這些變化共同推動了採購決策的更加精細化，將病人安全、臨床醫生體驗和全生命週期成本置於設備選擇的核心。

關稅引發的供應鏈變化對零件採購、到岸成本趨勢、供應商多元化和採購彈性策略的連鎖反應

近期美國政策引發的關稅變動為心肺體外迴圈供應鏈帶來了新的挑戰，影響了成本結構、庫存策略和採購決策。依賴跨境生產的零件製造商，例如氧合器膜所需的特種聚合物、導管和泵殼所需的精密金屬零件以及醫藥級塗層，面臨關稅風險增加的局面，這將改變其到岸成本。因此，許多供應商正在重新評估其供應鏈結構，以在維持服務水準的同時保護利潤率。

為此，醫院和心臟中心的採購團隊正在擴展供應商資格框架，並優先考慮多源採購策略，以降低單一供應商風險。在關稅導致進口零件相對成本上升的情況下，一些原始設備製造商 (OEM) 正在加快本地化進程，或重新談判合約以納入關稅轉嫁條款。這些措施標誌著採購模式正從純粹的價格主導轉向更具韌性的採購策略，後者更加重視前置作業時間的確定性和零件的可追溯性。

監管和合約方面的影響也十分顯著。採購部門和醫療系統越來越要求供應商在更換製造地時，提供關於零件來源和保固範圍的透明資訊。如果為了應對關稅影響而進行零件替換，導致產品規格發生變化，臨床醫生和灌注團隊可能需要經歷一段過渡期。因此，醫療相關人員應制定檢驗週期、培訓更新和庫存緩衝計劃，以避免在供應商進行製造地長期重組期間手術安排中斷。

詳細的細分分析揭示了產品系列、臨床應用、最終用戶環境和技術選擇如何相互作用，從而影響採購和採用模式。

詳細的細分市場分析為產品開發、臨床應用和銷售策略提供了切實可行的指導。按產品類型分類，市場格局包括附件、插管、過濾器、氧合器和幫浦。附件包括儲液器和導管，而插管則根據解剖結構和血流需求設計用於動脈或靜脈。過濾器分為血液濃縮器和白血球去除過濾器，它們在體液管理和發炎調節中發揮不同的作用。氧合器則分為膜式和微孔式兩種結構。在膜式氧合器中，平板式和中空纖維式結構在表面積、預充能力和氣體交換效率方面各有優劣。泵浦分為離心式和滾壓式兩種技術，每種技術都會影響溶血風險、維護特性以及與輔助監測系統的兼容性。

應用領域根據使用情境分為成人、新生兒和兒科，會對設備尺寸、預充策略和電路設計產生顯著影響。新生兒和兒科應用需要特殊的插管和氧合器功能，以及小批量、高精度的解決方案，而成人應用則更注重耐用性和吞吐量。將最終用戶細分為門診手術中心、心臟外科中心和醫院，會影響採購週期和服務預期。門診中心優先考慮簡化的耗材和快速周轉率，心臟外科中心通常需要複雜、可自訂的系統，而醫院則需要在各種病例組合中兼顧多功能性和成本控制。

在技​​術細分中，塗層類型和運作模式是關鍵決定因素。塗層選項包括肝素塗層和非塗層表面，塗層迴路為高血栓風險患者或尋求減少全身性抗凝血治療的患者提供了臨床依據。運作模式分為非搏動式和搏動式系統，此選擇會影響生理支持特性和系統複雜性。總而言之，這些細分視角構成了一個矩陣，製造商和醫療服務提供者可以利用該矩陣來調整產品系列，使其與臨床需求、採購限制和使用者偏好觀點。

區域監管差異、採購慣例和臨床能力如何影響美洲、歐洲、中東和非洲以及亞太地區的商業化和服務策略

區域趨勢對美洲、歐洲、中東和非洲以及亞太市場的臨床實踐、監管路徑和商業策略有顯著影響。在美洲，大型醫院系統和學術機構是主要的機構買家，他們要求產品具備可靠的臨床療效證據、完善的服務網路，並能與電子健康記錄 (EHR) 和灌注監測平台無縫整合。該地區的支付模式和醫院採購週期鼓勵選擇性能持久耐用的設備，並建立長期的供應商夥伴關係。

在歐洲、中東和非洲地區（EMEA），監管的多樣性和報銷政策的差異要求製造商尋求多條核准途徑，並收集統一的臨床數據以支援價值評估資料。該地區的採購往往側重於成本效益和全生命週期支持，涵蓋從先進的心臟中心到資源匱乏的醫療機構等各種醫療服務環境。亞太地區的特點是心臟外科手術能力的快速擴張、對本地製造的投資以及對床邊診療最佳化的日益重視。亞太地區的需求成長主要受手術量增加以及對醫療設備可負擔性和本地服務能力的期望不斷提高的驅動。

臨床通訊協定、人員訓練架構和廢棄物管理法規的區域差異會對設備設計和售後服務產生實際影響。製造商應根據區域報銷差異、當地臨床證據的產生以及快速技術支援的後勤需求，調整打入市場策略。與區域分銷商建立策略合作夥伴關係，並投資於灌注團隊和手術人員的培訓，對於推動這些多元化市場中的產品普及至關重要。

現有製造商、專業創新者和以服務為導向的供應商之間的競爭和策略應對，決定了市場領導地位和商業性差異化。

心肺體外迴圈領域的競爭動態由三者構成：既有成熟的外科設備製造商，也有專業的體外循環系統供應商，還有專注於利基創新技術的新興企業。現有企業憑藉涵蓋耗材、設備和綜合服務合約的廣泛產品系列，形成了高昂的轉換成本和較長的產品生命週期。同時，規模較小的公司和新興企業則透過新型薄膜材料、低預充量氧合器設計以及專科中心和研究型醫院的先進泵浦控制演算法來實現差異化競爭。

市場參與企業正積極與臨床中心合作，共同開發下一代系統，檢驗新型塗層，並進行上市後研究，以證明其在實際應用中的益處。為因應採購壓力和關稅風險，供應鏈協作、契約製造模式和選擇性垂直整合是常見的策略。此外，他們還在投資數位化能力，例如設備遙測和預測性維護，以提高運轉率，並證明其價值遠超過初始購買成本。

銷售和商務團隊面臨的挑戰在於，如何清楚地向循環系統、心臟外科醫師和採購委員會闡明產品的臨床價值。這需要提供證據，證明產品在相關生命週期內能夠降低併發症發生率、簡化工作流程並降低總營運成本，而不僅依賴價格作為差異化因素。能夠將可靠的臨床支援、快速回應的技術服務和靈活的合約選項相結合的公司，將更容易獲得醫院系統和專科心臟中心的青睞。

製造商和供應商可採取的切實可行的策略重點，以最佳化其產品組合、保障供應鏈安全、產生臨床證據、拓展服務範圍並實現永續性目標。

產業領導者可以採取切實可行的優先事項，在應對營運瓶頸的同時，鞏固市場地位並提升臨床療效。首先，應優先最佳化產品組合，使產品複雜性與核心終端使用者需求相符；在臨床證據不支持差異化的情況下，減少SKU數量；並將創新重點放在新生兒、兒科和成人等細分市場需要獨特解決方案的領域。其次，應投資於供應鏈韌性，實現關鍵零件供應商多元化，並協商合約保護條款，以降低關稅和物流波動帶來的風險。

第三，我們將深化臨床夥伴關係，以支持實證醫學證據的生成，包括建立註冊登記系統和進行合作研究，檢驗膜類型、塗層和脈動模式在相關患者群體中的益處。第四，我們將拓展售後服務模式，納入遠距離診斷、預測性維護和培訓項目，從而減少停機時間，並提高灌注醫護人員的信心。第五，我們將根據不同地區最佳化市場推廣策略，重點關注歐洲市場的監管合規性和價值提案材料，美洲市場的性能和服務，以及亞太地區的可負擔性和本地化支持。

最後，將永續性和減少廢棄物融入產品和包裝設計中，以滿足醫療機構的 ESG 目標和不斷發展的採購標準——共同實施這些措施可以幫助製造商和供應商在不斷變化的政策和供應鏈環境中實現可衡量的臨床效益、增強商業性差異化並降低營運風險。

研究的基礎研究採用嚴謹的混合方法，結合臨床醫生訪談、監管審查和技術文獻，以檢驗營運見解並得出策略重點。

本分析的研究結合了對臨床醫生、循環系統、採購人員和行業高管的定性訪談，以及透過監管文件、技術白皮書和同行評審的臨床文獻進行的二次檢驗。主要研究著重於了解代表性醫院、心臟中心和門診手術中心的實際設備表現、臨床醫生偏好、服務期望和採購限制。受訪者特意包括服務成人和兒童患者的循環系統，以了解設備在各種臨床應用頻譜下的表現。

二手資料提供了薄膜材料、泵浦機構和塗層技術的技術背景，並用於檢驗調查方法中出現的主題。採用橫斷面主題分析法，辨識出反覆出現的營運挑戰、技術重點與採購行為。然後，將這些主題與產品細分和區域特徵相匹配，從而得出切實可行的建議。透過反覆的專家檢驗以及對影響設備設計和標籤的最新法規資訊的審查，確保了建議的準確性和相關性。

這種綜合方法促成了切實可行的綜合分析，指導了商業策略、臨床應用路徑和採購決策，而無需依賴推測性的市場預測。最終形成了一個堅實的證據基礎，使相關人員能夠確定投資優先事項、調整市場推廣策略，並使產品藍圖與臨床和營運實際情況相符。

本文綜合闡述了各項策略要務，闡明了技術創新、供應鏈韌性和精準商業性策略如何協同作用，以支持臨床應用和營運穩定性。

總之，心肺體外迴圈領域正處於一個轉折點，技術創新、政策壓力和不斷變化的臨床需求相互交織，重塑採購和臨床實踐。氧合器設計、幫浦機制和表面塗層技術的進步帶來了切實的臨床益處，但其成功應用取決於與服務安排、臨床醫生培訓和籌資策略的精心協調。關稅導致的供應鏈調整凸顯了採購管道多元化和提高組件採購路徑透明度的必要性，而不同地區法規和臨床能力的差異則要求根據特定市場採取量身定做的方法。

專注於建立穩健供應鏈、聚焦產品系列、建立強大的臨床夥伴關係關係以及提供全面售後服務支援的製造商，將更有能力滿足包括醫院、心臟中心和門診機構在內的醫療機構的複雜需求。同樣，將設備選擇與員工培訓、庫存管理和永續性考量相結合的醫療服務提供者，將能夠最大限度地提高臨床療效和營運效率。本摘要中概述的策略行動，為希望在不久的將來平衡創新應用與切實可行的營運風險管理的相關人員提供了藍圖。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 在小兒心臟手術中擴大採用小型化體外循環系統（以減少預充量和發炎反應）
  • 將即時血流動力學監測感測器整合到心肺體外迴圈迴路中，以提高患者安全性和治療效果
  • 開發生物相容性氧合器膜塗層，以減少體外循環手術期間的血液損傷和術後併發症
  • 攜帶式體外生命支持在加護治療環境中緊急轉運場景中的出現
  • 從滾壓泵技術過渡到磁浮離心式幫浦，以最佳化血流穩定性並最大限度地減少手術期間的溶血。
  • 擴大一次性幫浦和氧合器模組的規模，以簡化滅菌工作流程並防止污染風險。
  • 在體外循環手術中引入人工智慧演算法，用於預測灌注參數管理和自動系統警報

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章心肺體外迴圈裝置市場（依產品類型分類）

  • 配件
    • 水庫
    • 管子
  • 套管
    • 動脈
    • 靜脈注射用
  • 篩選
    • 血液濃縮器
    • 白血球去除裝置
  • 人工肺
    • 膜類型
      • 平板型
      • 中空纖維
    • 微孔
  • 泵浦
    • 離心式
    • 滾筒

第9章 依應用分類的心肺體外迴圈裝置市場

  • 成人版
  • 新生
  • 孩子們

第10章 以最終用戶分類的心肺體外迴圈裝置市場

  • 門診手術中心
  • 心臟外科中心
  • 醫院

第11章 依技術分類的心肺體外迴圈裝置市場

  • 塗層類型
    • 肝素塗層
    • 未塗層
  • 按操作模式
    • 非脈動
    • 脈動

第12章心肺體外迴圈裝置市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章心肺體外迴圈裝置市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國心肺體外迴圈裝置市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Terumo Corporation
    • LivaNova PLC
    • Medtronic plc
    • Getinge AB
    • Nipro Corporation
    • JMS Co., Ltd
    • XENIOS AG
    • Fresenius Medical Care AG & Co. KGaA
    • Baxter International Inc.
    • Haemonetics Corporation
Product Code: MRR-757B1C9CB0B8

The Cardiopulmonary Bypass Equipment Market is projected to grow by USD 456.10 million at a CAGR of 4.53% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 319.92 million
Estimated Year [2025] USD 334.74 million
Forecast Year [2032] USD 456.10 million
CAGR (%) 4.53%

A strategic overview placing cardiopulmonary bypass equipment within clinical practice, procurement priorities, technological progress and institutional decision frameworks

This executive summary opens by situating cardiopulmonary bypass equipment within the broader continuum of cardiac surgical care, where device reliability, biocompatibility, and procedural efficiency directly influence clinical outcomes. The equipment set covered spans devices and disposables that enable extracorporeal circulation during cardiac procedures, and it interacts closely with clinical protocols, perfusionist practice, and institutional procurement priorities. As teams across hospitals and specialized cardiac centers recalibrate workflows to optimize outcomes and contain costs, understanding the interplay among device functionality, user ergonomics, and patient safety has become essential.

Clinical adoption is shaped by both micro-level operational needs-such as ease of setup, priming volumes, and compatibility with monitoring systems-and macro-level forces including regulatory scrutiny and supply chain resilience. Technological advances in oxygenator membrane design and pump mechanics have reduced complication rates and simplified perioperative management, yet they have also introduced new decision criteria around training, disposables inventory, and vendor consolidation. Consequently, hospital administrators and perfusion leaders must synthesize clinical performance data with procurement considerations to select systems that align with institutional case mix and long-term capital plans.

The introduction concludes by framing the remainder of this summary as a practical synthesis: it highlights structural shifts, policy influences, segmentation nuances, regional dynamics, competitor behaviors, and targeted recommendations that together form a foundation for immediate strategic action by manufacturers, providers, and investors.

How advancements in membrane design, pump mechanics, coatings, and clinical workflows are collectively reshaping procurement, clinical practice, and device development pathways

The landscape for cardiopulmonary bypass equipment is undergoing transformative shifts driven by converging clinical priorities, engineering innovation, and heightened expectations for safety and efficiency. Advances in membrane oxygenator materials, including the refinement of hollow fiber geometries and flat plate designs, are delivering improved gas exchange characteristics while reducing blood trauma. At the same time, pump technologies have evolved with more durable centrifugal mechanics and more precise roller pump controls, altering perfusionist workflows and inventory configurations.

Beyond device evolution, systemic change is evident in the emphasis on coatings and surface treatments to mitigate thrombogenicity. Heparin-coated circuits and alternative biocompatible coatings are increasingly considered where anticoagulation management is complex, creating a differentiated value proposition between coated and non-coated systems. Mode of operation considerations-non-pulsatile versus pulsatile flow-are also influencing hospital purchasing decisions as clinicians weigh hemodynamic fidelity against device complexity and cost of disposables.

Operationally, there is a clear shift toward integrated circuit sets and single-use platforms that promise faster turnover and reduced contamination risk, but these benefits must be balanced against waste management and sustainability goals. In parallel, adoption patterns in neonatal and pediatric subsegments demand specialized cannulae and oxygenators sized for lower flow volumes and different priming strategies, prompting suppliers to refine product families to match patient demographics. Taken together, these shifts are driving a more nuanced procurement dialogue that places patient safety, clinician experience, and lifecycle total cost at the center of equipment selection.

The ripple effects of tariff-induced supply chain shifts on component sourcing, landed cost dynamics, supplier diversification, and procurement resilience strategies

Recent tariff developments originating from United States policy actions have introduced novel considerations across supply chains for cardiopulmonary bypass equipment, affecting cost structures, inventory strategies, and sourcing decisions. Manufacturers that rely on cross-border production of components such as specialized polymers for oxygenator membranes, precision metalwork for cannulae and pump housings, or pharmaceutical-grade coatings face increased exposure to duties that can alter landed costs. As a result, many suppliers are reassessing their supply chain architectures to preserve margin while maintaining service levels.

Procurement teams at hospitals and cardiac centers are responding by expanding supplier qualification frameworks and prioritizing dual-source strategies that reduce single-vendor risk. Where tariffs increase the relative cost of imported components, some original equipment manufacturers are accelerating localization efforts or renegotiating contracts to include tariff pass-through clauses. These measures underscore a shift from purely price-driven sourcing to a more resilient procurement posture that values lead-time assurance and component traceability.

Regulatory and contracting effects are also apparent: purchasing groups and health systems increasingly require transparency on the origin of components and warranty implications when manufacturing locations change. Clinicians and perfusion teams may face transition periods when product specifications shift due to component substitutions intended to mitigate tariff impacts. Therefore, institutional stakeholders should plan for validation cycles, training refreshers, and inventory buffers to avoid disruptions to surgical schedules while suppliers pursue longer-term realignment of manufacturing footprints.

Deep segmentation analysis revealing how product families, clinical applications, end-user environments, and technology choices interact to shape procurement and adoption patterns

Analyzing the market through detailed segmentation reveals actionable implications for product development, clinical adoption, and sales strategies. When viewed by product type, the landscape encompasses Accessories, Cannulae, Filters, Oxygenators, and Pumps; Accessories include Reservoirs and Tubing, and Cannulae comprise Arterial and Venous variants designed for distinct anatomical and flow requirements. Filters span Hemoconcentrators and Leukocyte Filters, which play differentiated roles in fluid management and inflammatory modulation, while Oxygenators are available in Membrane and Microporous constructs. Within membrane oxygenators, Flat Plate and Hollow Fiber architectures present tradeoffs in surface area, priming volume, and gas transfer efficiency. Pumps bifurcate into Centrifugal and Roller technologies, each with implications for hemolysis risk, maintenance profiles, and compatibility with ancillary monitoring systems.

Application segmentation differentiates adult, neonatal, and pediatric use cases, a distinction that materially affects device sizing, priming strategies, and circuit design. Neonatal and pediatric applications demand low-volume, high-precision solutions with specialized cannulae and oxygenator characteristics, whereas adult applications often emphasize durability and throughput. End user segmentation across Ambulatory Surgery Centers, Cardiac Surgery Centers, and Hospitals influences purchasing cycles and service expectations; ambulatory centers prioritize streamlined disposables and rapid turnover, cardiac surgery centers often demand high-performance customizable systems, and hospitals balance versatility with cost containment across broader case mixes.

Technology segmentation highlights coating type and mode of operation as pivotal decision variables. Coating options include Heparin Coated and Non Coated surfaces, with coated circuits offering a clinical rationale in patients at higher thrombotic risk or where lower systemic anticoagulation is desirable. Mode of operation divides into Non Pulsatile and Pulsatile systems, a choice that informs both physiological support characteristics and system complexity. Collectively, these segmentation lenses create a matrix that manufacturers and providers can use to align product portfolios with clinical needs, procurement constraints, and user preferences.

How regional regulatory diversity, procurement practices and clinical capacity across the Americas, Europe Middle East & Africa, and Asia-Pacific shape commercialization and service strategies

Regional dynamics exert a significant influence on clinical practice, regulatory pathways, and commercial strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets. In the Americas, institutional purchasing is characterized by large hospital systems and academic centers that demand robust evidence of clinical efficacy, strong service networks, and integration with electronic health records and perfusion monitoring platforms. Payment models and hospital procurement cycles in this region incentivize durable equipment performance and long-term vendor partnerships.

In Europe, Middle East & Africa, regulatory diversity and reimbursement variability require manufacturers to pursue harmonized clinical data that can support multiple approval pathways and value dossiers. Procurement in this region often emphasizes cost-effectiveness and lifecycle support across disparate healthcare delivery settings, from advanced cardiac centers to under-resourced facilities. The Asia-Pacific region is marked by rapid expansion of cardiac surgical capacity, investment in local manufacturing, and a growing emphasis on point-of-care optimization. Demand in Asia-Pacific is driven by both rising procedure volumes and evolving expectations for device affordability and local service capabilities.

Across regions, differences in clinical protocols, staff training paradigms, and waste management regulations create practical implications for device design and aftersales service. Manufacturers should calibrate market entry strategies to address regional reimbursement nuances, local clinical evidence generation, and the logistical requirements of providing responsive technical support. Strategic partnerships with regional distributors and investments in education for perfusion teams and surgical staff will be critical to unlock adoption across these heterogeneous markets.

Competitive behaviors and strategic responses among established manufacturers, focused innovators, and service-oriented providers that define market leadership and commercial differentiation

Competitive dynamics in the cardiopulmonary bypass equipment space are defined by a mix of established surgical device manufacturers, specialized perfusion system providers, and emerging technology entrants focused on niche innovations. Incumbent manufacturers leverage broad portfolios that span disposables, capital equipment, and integrated service contracts, creating high switching costs and extended product lifecycles. Meanwhile, smaller firms and start-ups push differentiation through novel membrane materials, low-priming-volume oxygenator designs, and advanced pump control algorithms that appeal to specialty centers and research hospitals.

Market participants are increasingly pursuing partnerships with clinical centers to co-develop next-generation systems, validate novel coatings, and run post-market surveillance studies that demonstrate real-world benefits. Supply chain collaborations, contract manufacturing models, and selective vertical integration are common strategic responses to procurement pressures and tariff exposure. Additionally, companies are investing in digital capabilities around device telemetry and predictive maintenance to enhance uptime and demonstrate value beyond the initial purchase.

For sales and commercial teams, the imperative is to articulate clinical value clearly to perfusionists, cardiac surgeons, and purchasing committees. This includes providing evidence of reduced complication rates, simplified workflows, and total cost of operation over relevant lifecycle horizons without relying solely on price as the differentiator. Firms that can combine robust clinical support, rapid technical service, and flexible contracting options will gain traction among hospital systems and specialized cardiac centers.

Practical strategic priorities for manufacturers and providers to optimize portfolios, secure supply chains, generate clinical evidence, expand service offerings, and address sustainability objectives

Industry leaders can pursue a set of actionable priorities to strengthen market positions and support clinical outcomes while addressing operational constraints. First, prioritize portfolio rationalization that aligns product complexity with core end-user needs, reducing SKUs where clinical evidence does not support differentiation and concentrating innovation where neonatal, pediatric, or adult subsegments demand unique solutions. Second, invest in supply chain resilience by diversifying suppliers of critical components and negotiating contractual protections that mitigate tariff and logistics volatility.

Third, deepen clinical partnerships that support evidence generation, including registries and collaborative studies that validate the benefits of membrane types, coatings, and pulsatile modality in relevant patient cohorts. Fourth, expand aftersales service models to include remote diagnostics, predictive maintenance, and training programs that reduce downtime and improve adoption confidence among perfusion staff. Fifth, tailor go-to-market approaches by region: emphasize regulatory alignment and value dossiers in Europe, performance and service in the Americas, and affordability plus local support in Asia-Pacific.

Finally, integrate sustainability and waste reduction into product and packaging design to meet institutional ESG goals and evolving procurement criteria. Executed together, these actions will help manufacturers and providers deliver measurable clinical benefits, strengthen commercial differentiation, and reduce operational risk in a shifting policy and supply chain environment.

A rigorous mixed-methods research approach combining clinician interviews, regulatory review, and technical literature to validate operational insights andinform strategic priorities

The research underlying this analysis synthesizes primary qualitative interviews with clinicians, perfusionists, procurement leaders, and industry executives alongside secondary validation from regulatory filings, technical white papers, and peer-reviewed clinical literature. Primary engagement focused on understanding real-world device performance, clinician preferences, service expectations, and procurement constraints across a representative set of hospitals, cardiac centers, and ambulatory surgical facilities. Interview sampling deliberately included perfusionists working with both adult and pediatric populations to capture device performance across the clinical spectrum.

Secondary sources provided technical context on membrane materials, pump mechanics, and coating science and were used to corroborate themes that emerged in interviews. The methodology applied a cross-sectional thematic analysis to identify recurring operational pain points, technology priorities, and procurement behaviors, and these themes were mapped against product segmentation and regional dynamics to derive actionable recommendations. To ensure accuracy and relevance, the analysis included iterative validation with subject matter experts and a review of recent regulatory communications that affect device design and labeling.

This combined approach produced a pragmatic synthesis designed to inform commercial strategy, clinical adoption pathways, and procurement decisions without relying on speculative market projections. The result is a robust evidence base that stakeholders can use to prioritize investments, modify go-to-market strategies, and align product roadmaps with clinical and operational realities.

Synthesis of strategic imperatives showing how technology, supply chain resilience and targeted commercial approaches converge to support clinical adoption and operational stability

In conclusion, the cardiopulmonary bypass equipment environment is at an inflection point where technology improvements, policy pressures, and evolving clinical expectations converge to reshape procurement and clinical practice. Advances in oxygenator design, pump mechanics, and surface coatings are delivering tangible clinical benefits, yet their successful adoption depends on careful alignment with service capabilities, clinician training, and procurement strategies. Tariff-induced supply chain adjustments have underscored the need for diversified sourcing and greater transparency around component provenance, while regional differences in regulation and clinical capacity call for tailored market approaches.

Manufacturers that emphasize resilient supply chains, focused product portfolios, robust clinical partnerships, and comprehensive aftersales support will be better positioned to meet the complex needs of hospitals, cardiac centers, and ambulatory facilities. Similarly, providers that integrate device selection with staff training, inventory management, and sustainability considerations will maximize clinical outcomes and operational efficiencies. The strategic actions outlined in this summary offer a roadmap for stakeholders seeking to balance innovation adoption with pragmatic operational risk management in the near term.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of miniaturized extracorporeal circulation systems in pediatric cardiac surgery to reduce priming volumes and inflammatory response
  • 5.2. Integration of real-time hemodynamic monitoring sensors into cardiopulmonary bypass circuits for enhanced patient safety and outcomes
  • 5.3. Development of biocompatible oxygenator membrane coatings to mitigate blood trauma and reduce postoperative complications in bypass procedures
  • 5.4. Emergence of portable extracorporeal life support devices for emergency transport scenarios in critical care settings
  • 5.5. Transition from roller pump technology to magnetic levitation centrifugal pumps to optimize flow stability and minimize hemolysis during surgeries
  • 5.6. Expansion of single-use disposable pump and oxygenator modules to streamline sterilization workflows and prevent contamination risks
  • 5.7. Implementation of artificial intelligence algorithms for predictive perfusion parameter management and automated system alerts during bypass

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiopulmonary Bypass Equipment Market, by Product Type

  • 8.1. Accessories
    • 8.1.1. Reservoirs
    • 8.1.2. Tubing
  • 8.2. Cannulae
    • 8.2.1. Arterial
    • 8.2.2. Venous
  • 8.3. Filters
    • 8.3.1. Hemoconcentrators
    • 8.3.2. Leukocyte Filters
  • 8.4. Oxygenators
    • 8.4.1. Membrane
      • 8.4.1.1. Flat Plate
      • 8.4.1.2. Hollow Fiber
    • 8.4.2. Microporous
  • 8.5. Pumps
    • 8.5.1. Centrifugal
    • 8.5.2. Roller

9. Cardiopulmonary Bypass Equipment Market, by Application

  • 9.1. Adult
  • 9.2. Neonatal
  • 9.3. Pediatric

10. Cardiopulmonary Bypass Equipment Market, by End User

  • 10.1. Ambulatory Surgery Centers
  • 10.2. Cardiac Surgery Centers
  • 10.3. Hospitals

11. Cardiopulmonary Bypass Equipment Market, by Technology

  • 11.1. Coating Type
    • 11.1.1. Heparin Coated
    • 11.1.2. Non Coated
  • 11.2. Mode Of Operation
    • 11.2.1. Non Pulsatile
    • 11.2.2. Pulsatile

12. Cardiopulmonary Bypass Equipment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cardiopulmonary Bypass Equipment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cardiopulmonary Bypass Equipment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Terumo Corporation
    • 15.3.2. LivaNova PLC
    • 15.3.3. Medtronic plc
    • 15.3.4. Getinge AB
    • 15.3.5. Nipro Corporation
    • 15.3.6. JMS Co., Ltd
    • 15.3.7. XENIOS AG
    • 15.3.8. Fresenius Medical Care AG & Co. KGaA
    • 15.3.9. Baxter International Inc.
    • 15.3.10. Haemonetics Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CARDIOPULMONARY BYPASS EQUIPMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CARDIOPULMONARY BYPASS EQUIPMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CARDIOPULMONARY BYPASS EQUIPMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY RESERVOIRS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY RESERVOIRS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY RESERVOIRS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY RESERVOIRS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY RESERVOIRS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY RESERVOIRS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TUBING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TUBING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TUBING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TUBING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TUBING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TUBING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ARTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ARTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ARTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ARTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ARTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ARTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY VENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY VENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY VENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY VENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY VENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY VENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEMOCONCENTRATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEMOCONCENTRATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEMOCONCENTRATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEMOCONCENTRATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEMOCONCENTRATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEMOCONCENTRATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY LEUKOCYTE FILTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY LEUKOCYTE FILTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY LEUKOCYTE FILTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY LEUKOCYTE FILTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY LEUKOCYTE FILTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY LEUKOCYTE FILTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FLAT PLATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FLAT PLATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FLAT PLATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FLAT PLATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FLAT PLATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FLAT PLATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOLLOW FIBER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOLLOW FIBER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOLLOW FIBER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOLLOW FIBER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOLLOW FIBER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOLLOW FIBER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MICROPOROUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MICROPOROUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MICROPOROUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MICROPOROUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MICROPOROUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MICROPOROUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ROLLER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ROLLER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ROLLER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ROLLER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ROLLER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ROLLER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NEONATAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NEONATAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NEONATAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NEONATAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NEONATAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NEONATAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CARDIAC SURGERY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CARDIAC SURGERY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CARDIAC SURGERY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CARDIAC SURGERY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CARDIAC SURGERY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CARDIAC SURGERY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEPARIN COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEPARIN COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEPARIN COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEPARIN COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEPARIN COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEPARIN COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON PULSATILE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON PULSATILE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON PULSATILE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON PULSATILE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON PULSATILE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON PULSATILE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PULSATILE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PULSATILE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PULSATILE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PULSATILE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PULSATILE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PULSATILE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET